Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: RMD Open, 8, 2, Article e002293, S. e002293-1-e002293-11
- Event
-
Veröffentlichung
- (where)
-
Bochum
- (who)
-
Ruhr-Universität Bochum
- (when)
-
2022
- Creator
-
Andreica, Ioana
Blazquez-Navarro, Arturo
Sokolar, Jan
Anft, Moritz
Kiltz, Uta
Pfänder, Stephanie
Vidal Blanco, Elena
Westhoff, Timm
Babel, Nina
Stervbo-Kristensen, Ulrik
Baraliakos, Xenofon
- URN
-
urn:nbn:de:hbz:294-103589
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Andreica, Ioana
- Blazquez-Navarro, Arturo
- Sokolar, Jan
- Anft, Moritz
- Kiltz, Uta
- Pfänder, Stephanie
- Vidal Blanco, Elena
- Westhoff, Timm
- Babel, Nina
- Stervbo-Kristensen, Ulrik
- Baraliakos, Xenofon
- Ruhr-Universität Bochum
Time of origin
- 2022
Other Objects (12)
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug
Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug
Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug